Group items tagged

Major Highlights of the Sugar Beet Seeds Market report study: A detailed look at the global Sugar Beet Seeds Industry The report analyzes the global Sugar Beet Seeds market and provides its stakeholders with significant actionable insights The report has considered all the major developments in the recent past, helping the users of the report with recent industry updates The report study is expected to help the key decision-makers in the industry to assist them in the decision-making process The study includes data on market intelligence, changing market dynamics, current and expected market trends, etc. The report comprises an in-depth analysis of macroeconomic and microeconomic factors affecting the global Sugar Beet Seeds market Market Ecosystem and adoption across market regions Major trends shaping the global Sugar Beet Seeds market Historical and forecast size of the Sugar Beet Seeds market in terms of Revenue (USD Million) Recent industry development and consumer preference trends Competitive Landscape and player positioning analysis for the global Sugar Beet Seeds market Key products and solution offerings by major players and business strategies adopted Recommendations for new market entrants and current players operating in the market space Analysis of niche and potential segments (type, application, and regions/countries) anticipated to observed promising growth Key challenges faced by operating players in the market space Analysis of major risks associated with the market operations Get FREE PDF Copy @ https://www.marketresearchstore.com/sample/sugar-beet-seeds-market-794502?utm_source=diigo.com-VPL&utm_medium=Varsha

Breast cancer is at the top in the list of women diseases that cause death in developed and the developing countries. In the developed countries the number of breast cancer victims is increasing rapidly due to the various reasons such as adoption of western life style, increased urbanization and increased life expectancy.

Have you any emotional or physical issues with your health? Get the EFT emotional freedom techniques and matrix reimprinting consultation session from Kalleen Henderson.

Have you any emotional or physical issues with your health? Get the EFT emotional freedom techniques and matrix reimprinting consultation session from Kalleen Henderson.

Kalleen Henderson, M.A. specializes in EFT (Emotional Freedom Technique) and Matrix Reimprinting to rapidly release stress, physical/emotional pain and new or longstanding issues.

(NaturalNews) An anti-cancer compound found in broccoli and cabbage stops breast cancer by lowering the activity of an enzyme associated with rapidly advancing breast cancer, according to a recent study from the University of California, Berkley. That compound was indole-3-carbinol (I3C). Today, scientists have found that diindolymethane (DIM), a molecule found in I3C, is the chemoprotective compound that gets the job done. According to them, DIM is the better choice for women wanting to halt breast

Persons having prostate cancer or breast cancer cannot use testosterone replacement therapy because it can cause the cancer to grow more rapidly. Testosterone therapy is used to improve low T levels in human body. However, it has number of negative impacts that everyone should know before using it.

Community pharmacy is at the heart of one of the most ambitious clinical trials ever undertaken by the UK's primary care network, says senior academic pharmacist Professor Mahendra Patel. The PANORAMIC trial has been designed to rapidly evaluate several antiviral treatments over time that could help people at high risk of Covid-19 recover sooner, prevent the need for hospital admission and so ease the burden on the NHS. The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) is a national priority trial led by Oxford University's Primary Care Clinical Trials Unit. Lead investigators say the study will enable early and rapid testing of novel antiviral agents and help repurpose existing drugs against Covid-19. As soon as the trial is set up for delivery, it will be open to eligible participants from across the UK. Prof Patel, a key member of the trial's core team, said: "I'm really excited with this news and also by the prospect that there is a huge potential for pharmacy teams to help play a vital role in supporting this highly ambitious trial, as they have with the PRINCIPLE trial, now the world's largest community based clinical trial for Covid19."

A news report suggests the Department of Health and Social Care is aiming to be ready to start charging for Covid-19 tests which are currently free at the end of June. Britain has been increasingly dependent on rapid testing to try to tackle the more-transmissible Omicron variant, which has spread rapidly through the population but is less severe. The government has previously said it will end the universal free provision of easy-to-use lateral flow devices (LFDs) at a "later stage", with individuals and businesses bearing the cost. The Department of Health has declined to say what the tests cost, citing commercial contracts. One source has told the Reuters news agency they can run to £30 for a pack of seven. Free pick up from pharmacies The tests have been made freely available to order online or pick up from local pharmacies since April. The UK Health Security Agency said that between December 30 and January 5 more than 8 million LFDs were conducted, the highest weekly figure on record.

The Home Affairs Committee has called upon the government to revise its current drug policy, moving away from the exclusive 'abstinence only' approach towards a more practical strategy that highlights harm reduction. The HAC's recommendations also include the introduction of a national naloxone programme in England, with community pharmacies playing a central role in facilitating access. The committee published its comprehensive report on August 31, with key recommendations, including the 'urgent' reclassification of psychedelic drugs for therapeutic research; a pilot safe consumption facility program (long resisted by the Westminster Government despite Scottish lobbying); and enhanced provision and research on cannabis-based medicinal products (CBPMs). The report urged the establishment of a national naloxone programme in England, aligning with devolved nations. It also highlighted the role of community pharmacists and peer initiatives for effective distribution and administration. Furthermore, the report emphasises enhanced naloxone distribution for prison leavers. Naloxone is a medication capable of rapidly reversing heroin or methadone overdoses, potentially saving lives.

The NHS England has introduced a training programme for 1000 staff to broaden their community pharmacy roles, thereby improving patient access to services. Among them, 500 pharmacy staff will be trained to supervise pharmacists during prescription training, while the remaining 500 will provide support for various training, including pre and post-registration programmes for pharmacists and pharmacy technicians. According to the NHSE, pharmacist and pharmacy technician roles are rapidly evolving due to healthcare changes and increased demand for clinical services in community pharmacy. "There are 3,000 independent prescribing training spots available for 2023/24. Educational supervision is a crucial part of this to enable the ongoing transformation and skills development of the growing pharmacy workforce." The NHSE-funded training, scheduled to begin next month, will ensure that those involved in educational supervision, including Designated Supervisors (DSs), Pre-registration Trainee Pharmacy Technician education supervisors and Designated Prescribing Practitioners (DPPs), can effectively support learners.

Skelmersdale-based online pharmacy Chemist4U has secured a £12 million investment from Pitalia Capital, an equity investment company led by Anil Pitalia. Chemist4U is part of JCCO Healthcare, which also houses the weight management platform myBMI. Anil Pitalia is a health enthusiast, who heads SpaMedica, a company providing cataract surgery to the NHS. This investment will propel the group's expansion, with John Davies, Managing Partner of Pitalia Capital, joining the board, the company said. Moreover, it will facilitate the extension of services by myBMI in the realm of weight management. "Our goal is for Chemist4U to emerge as one of the largest NHS dispensing facilities in the country, while also providing vital support to our partners through our rapidly expanding outsourced dispensing services division," said said James O'Loan, Chief Executive Officer of both Chemist4U and myBMI, who joined Chemist4U as a superintendent pharmacist in 2012 before becoming CEO in 2018. Meanwhile, Anil Pitalia, Head of Pitalia Capital based in Bolton, cited the compelling growth potential as the driving force behind his investment in Chemist4U's next-day medicine delivery service.

The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS). The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI) in April. Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's judgment. "While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the industry from the surge in the branded medicine payment rates. "The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in line with comparator countries to unlock investment and growth."

In a rapidly evolving and competitive landscape, the pharmaceutical industry faces unique challenges when it comes to marketing its products and services. With stringent regulations, complex target audiences, and a need for trust and credibility, pharma companies need to employ effective marketing strategies to stand out in the crowd. In this blog article, we will explore some key marketing strategies for the pharma industry that can help boost their visibility, engage their target audience, and drive business growth. UNDERSTANDING THE UNIQUE LANDSCAPE The pharma industry operates in a highly regulated environment, where compliance and ethical considerations play a crucial role. Before diving into marketing strategies, it is essential to have a deep understanding of the industry's dynamics and the target audience. Researching the market, identifying patient needs, and studying the competitive landscape are vital steps in developing an effective marketing plan. EMBRACING DIGITAL TRANSFORMATION Digital transformation has revolutionized marketing across industries, and the pharma sector is no exception. Embracing digital channels and technologies can significantly enhance the reach and impact of marketing efforts. Pharma companies can leverage social media platforms, create engaging content, and build online communities to connect with patients, healthcare professionals, and other stakeholders. Implementing robust digital marketing strategies allows for personalized messaging, real-time communication, and targeted campaigns that resonate with the target audience.

There is no doubt that the pandemic has changed the way healthcare professionals work within the primary care setting. The advent of Covid-19 meant that we all had to rapidly modify the way we supported and met the needs of patients, some of whom saw the services they usually took for granted, virtually cease overnight. There are around 15 million people in England living with long-term health conditions including asthma. These people have the greatest healthcare needs of the whole population with 50 per cent of all GP appointments and 70 per cent of all bed days taken by this cohort of patients, and their treatment and care absorbing 70 per cent of acute and primary care budgets in England. This situation isn't going to improve any time soon. In the past, most people had a single condition, today multi-morbidity is becoming the norm. At the start of the pandemic, the Royal College of General Practice and British Medical Association issued guidance to practices on prioritising workload. This included the importance of maintaining long-term condition reviews in asthma, COPD and diabetes, along with appropriate transition of at-risk warfarin patients. These reviews were deemed as essential workstreams for patients considered to be at high risk. Traditionally, the unique skills set of a pharmacist has meant that we have played a major role in supporting these patients. I work with a team of over 90 clinical pharmacists who, in partnership with individual practices, PCNs, CCGs and STPs, help with the long-term management of people with chronic conditions. But the onset of Covid-19 meant that we now had to plug a potential gap in service provision, and quickly.

There are few conditions that bring the degree of isolation, embarrassment and self-consciousness that bowel and urinary incontinence does. In the UK, about 14 million adults experience bladder control problems and 6.5 million have bowel control difficulties. Additionally, there are just under a million children in the UK experiencing continence conditions at any one time. Over £200 million is spent on personal incontinence products; this is in addition to over three times the same amount spent by the NHS. With a rapidly ageing population and unaddressed contributing factors, the significant financial burden, but importantly, the impact on the quality of life and dignity is devastating. We also know that cultural and communication difficulties can create barriers making treatment access and symptom alleviation more difficult. Considering the demography that this has a greater impact on - patients with a learning disability, non-English speakers and disabled patient - it becomes apparent this is a form of health inequality. However, pharmacy teams are best placed to tackle this head-on. Incontinence is the inability to control your bladder or bowel, so you accidentally lose urine from the bladder (urinary incontinence) or faeces from the bowel (bowel incontinence).

What skills does a pharmacist need these days? You'd think it would be sufficient to have a good understanding of pharmacy and the ability to offer a great patient service. Whilst this is true of course, the reality of the day to day role demands skills which most pharmacists have not been trained for as part of their formal qualification. At the very least, pharmacists find themselves responsible for running the pharmacy, managing people, managing processes and dealing with issues relating to customers, suppliers, surgeries, regulators and stakeholders. Even the most junior pharmacists quickly find themselves being accountable for the financial performance of their department and having to work within budgets or deliver on targets. Remarkably, despite the apparent lack of any formal training in these areas, pharmacists have been able to adapt and meet the challenges of whatever their job has thrown at them. Many pharmacists go even further, bringing out their inner entrepreneurial spirit to set up their own business. There are now over 6,000 pharmacy businesses owned by independent pharmacists, with this segment growing. Whilst pharmacists have historically adapted to their environments and picked up the necessary business skills, the rapidly changing landscape of pharmacy will require pharmacists to establish new skills to help ensure their businesses survive and thrive.

Johnson & Johnson said on Wednesday (January 18) that it was pulling the plug on a late-stage global trial of an HIV vaccine after the shot was found ineffective at preventing infections. The failure of the trial marks yet another setback in the search for a vaccine against a virus known to mutate rapidly and find unique ways to evade the immune system, and comes more than a year after another of J&J's HIV vaccine failed a study. "It's not the outcome we had hoped for, unfortunately," said a spokesperson for the National Institute of Allergy and Infectious Diseases, a J&J partner in the trial. "The development of a safe and effective HIV vaccine has been a considerable scientific challenge, but we will learn from this study and continue forward." The trial involved administering two different types of a shot, which uses a cold-causing virus to deliver the genetic code of HIV, spread over four vaccination visits in a year. J&J used similar technology for its COVID-19 vaccine. The study, which began in 2019, was conducted at over 50 sites and included about 3,900 gay men and transgender people - groups that are considered vulnerable to the infection.

The General Pharmaceutical Council (GPhC) temporary register which was expected to close on 30 September 2022 will continue for the next two years following a request from the secretary of state for health and social care. The temporary register was set up in 2020 after the then secretary of state asked the GPhC to use its emergency powers in order to rapidly register pharmacy professionals to assist in the national response to the Covid-19 emergency. The UK government has made this decision, which is referenced in its new 'Plan for Patients' in England to enable health professionals on the temporary registers to continue to support the health and social care system. The Government had previously announced that the temporary registers established by the health professional regulators were expected to close on 30 September 2022. The decision by the UK government to ask the regulators to keep the temporary registers means that pharmacy professionals on GPhC temporary register can continue to practise.

Being accepted and appearing attractive has always been among the most coveted goals in the world, which has given rise to the multibillion-dollar cosmetic and beauty industry. Fairy stories have been written about everlasting charm, and battles have been waged over attaining beauty. For the most part throughout history, people have continuously sought ways to improve their features using natural materials, and as technology advanced, they began to use technical methods like light therapy to accomplish the same goal. Chains of cosmetic clinics have sprouted up as a result of advances in technology and cosmetic materials, providing a variety of techniques to slow down the aging process or improve our appearance. So how can you set up your own beauty treatment and plastic surgery clinic to take advantage of this rapidly expanding market? Here are some pieces of advice! FIND QUALITY EQUIPMENT Your success depends on securing the greatest tools available for skin care and plastic surgery. Good quality equipment is a complete solution for distinguishing yourself from the competition. The initial step would be to locate different vendors. Using criteria like the cost of the equipment and replacement parts, the vendor's training, the company's reputation, the after-sales services, yearly maintenance, system performance, warranty, and extended warranties, you may narrow down your list of recommended suppliers. When selecting the appropriate medical supplies and equipment for your clinic, keep your budget in mind.

The European Union's population shrank for a second year running last year, the bloc's statistics office said on Monday, as the region reels from over two million deaths from the coronavirus. According to Eurostat, the population of the 27 countries that make up the bloc fell by close to 172,000 from the previous year and over 656,000 from January 2020. "In 2020 and 2021 the positive net migration no longer compensated for the negative natural change in the EU and, as a consequence, the EU total population has been decreasing," it said, pointing to impacts from the pandemic. The number of deaths began outstripping births in the EU a decade ago, but immigration from outside the bloc helped offset the gap until the first year of the pandemic. The previous time the EU had registered a fall in population was in 2011 - the only other time since 1960 - but this rapidly picked up due to net migration.